Ayala Pharmaceuticals, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q1 2019 to Q4 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Ayala Pharmaceuticals, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q1 2019 to Q4 2023.
- Ayala Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending December 31, 2023 was -$24.6M, a 154% decline year-over-year.
- Ayala Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending December 31, 2023 was -$52M, a 38.9% decline year-over-year.
- Ayala Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$52M, a 38.9% decline from 2022.
- Ayala Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$37.4M, a 110% decline from 2021.
- Ayala Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$17.8M, a 32.6% increase from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)